Evidence map›Paper›PMID 42149914›Full record

ArticlePLoS neglected tropical diseases2026

Dengue vaccine acceptability in Peru: A mixed-methods study in two dengue-endemic Peruvian cities.

Jorge L Cañari-Casaño, Emma B Ortega, Alfonso S Vizcarra, Roberto Camizan-Castro, E Jennifer Ríos López, Jhonny J Córdova López, Cristina Hidalgo, Luz M Moyano, Amy C Morrison, Valerie A Paz-Soldan

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jorge L Cañari-CasañoOne Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.
Emma B OrtegaDepartment of Tropical Medicine and Infectious Disease, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States of America.
Alfonso S VizcarraBehavioral Sciences Research Unit, Asociación Benéfica PRISMA, Iquitos, ‌‌Peru.
Roberto Camizan-CastroCenter for Global Health, Tumbes Facilities, Universidad Peruana Cayetano Heredia, Puerto el Cura Pizarro, Tumbes, Peru.
E Jennifer Ríos LópezBehavioral Sciences Research Unit, Asociación Benéfica PRISMA, Iquitos, ‌‌Peru.
Jhonny J Córdova LópezBehavioral Sciences Research Unit, Asociación Benéfica PRISMA, Iquitos, ‌‌Peru.
Cristina HidalgoBehavioral Sciences Research Unit, Asociación Benéfica PRISMA, Iquitos, ‌‌Peru.
Luz M MoyanoSchool of Medicine, Faculty of Health Sciences, Universidad Nacional de Tumbes,‌‌ Tumbes, Peru.
Amy C MorrisonDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, ‌‌University of California, Davis, California, United States of America.
Valerie A Paz-SoldanOne Health Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID https://orcid.org/0000-0002-1065-4919

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDengue poses a major public health challenge in Peru, with Piura and Iquitos experiencing recurrent outbreaks and limited control options. A dengue vaccine could complement current vector control strategies and reduce transmission, yet community perceptions and barriers to uptake in pre-implementation settings remain poorly understood. METHODOLOGY/PRINCIPAL

findingsOur mixed-methods study design was conducted in Piura and Iquitos, guided by the 5C's Framework of Vaccine Hesitancy. Sixteen focus group discussions (n = 147) explored acceptability and concerns regarding a hypothetical future dengue vaccine; a subsequent survey (n = 883) quantified vaccine acceptability. Dengue vaccine acceptability was operationalized using a theory-driven, multi-item outcome contrasting individuals willing to vaccinate ("acceptors") with those unsure about accepting vaccination ("unsure"). Multivariable logistic regression examined factors associated with vaccine uncertainty.

resultsUsing the multi-item, theory-driven classification, most (81.9%) survey participants were classified as "acceptors", 14.5% were "unsure", and 3.6% would refuse all vaccines ("refusers"). Qualitative findings underscored the need for clear information on efficacy, eligibility, and side effects, provided by trusted health professionals. In multivariable analysis, compared to acceptors, the "unsures" had more negative views towards COVID-19 vaccination (OR 2.17), higher technical or higher education (OR 3.33), and reduced confidence due to the rapid COVID-19 vaccine development (OR 2.17). The "unsures" also expressed less trust in vaccine benefits (OR 0.25), less willingness to pay for a dengue vaccine (OR 0.40), and lower knowledge of dengue transmission (OR 0.45) compared to the acceptors.

conclusionsAlthough most participants expressed willingness to receive a future dengue vaccine, vaccine uncertainty was primarily shaped by factors related to confidence, convenience, and communication. Mistrust in vaccines in general or residual mistrust linked to COVID-19 vaccination experiences, and concerns about vaccine development may hinder acceptance. Tailored communication, engaging trusted local leaders, and ensuring easy access are critical for successful dengue vaccination campaigns in these endemic regions.

Indexed as

DengueDengue VaccinesPatient Acceptance of Health CareVaccination HesitancyAdolescentAdultCitiesFemaleFocus GroupsHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedPeruSurveys and QuestionnairesVaccinationDengue Vaccines

Identifiers

PMID42149914
PMCPMC13193613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.